# A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors

> **NCT07498725** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **LARKSPUR BIOSCIENCES, INC.** · enrollment: 120 (estimated)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** LRK-4189 escalation
- **DRUG:** LRK-4189 expansion
- **DRUG:** LRK-4189 optimization
- **DRUG:** Chemo

## Key facts

- **NCT ID:** NCT07498725
- **Lead sponsor:** LARKSPUR BIOSCIENCES, INC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2029-06
- **Final completion:** 2029-06
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07498725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07498725, "A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07498725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*